GENinCode (LSE:GENI) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is GENinCode Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

GENinCode's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:GENI vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, GENinCode's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where GENinCode's Margin of Safety % (DCF Earnings Based) falls into.


GENinCode Business Description

Address Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.